Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from nonclinical studies of its novel
echinocandin antifungal CD101 and its CloudbreakTM antibacterial
immunotherapy CD201 will be presented at the 27th European Congress
of Clinical Microbiology and Infectious Diseases (ECCMID) in
Vienna, Austria from April 22-25 and at the 2017 Society for
Investigative Dermatology (SID) Annual Meeting in Portland, Oregon
from April 26-29.
“These presentations highlight the potential of our CD101 and
Cloudbreak platforms to address the unmet need for new therapeutic
approaches to treat and prevent fungal and bacterial infections --
particularly those that are resistant to existing anti-infectives,”
said Jeffrey Stein, Ph.D., president and chief executive officer of
Cidara. “These research findings reinforce our commitment to
investigate the full clinical utility of our novel anti-infective
product candidates across a range of formulations and
indications.”
A total of five presentations, comprising one oral presentation
and four posters, will highlight data evaluating the potential of
Cidara’s lead drug candidates, CD101 and CD201, to treat and
prevent serious infections. The ECCMID presentations include data
on CD101 in Candida auris, an emerging virulent fungal infection,
as well the compound’s potential for use as a subcutaneous
formulation for prophylactic treatment in candidiasis and
aspergillosis. Data from studies related to the antibacterial
activity of CD201 in Gram-negative bacterial infections will also
be presented at ECCMID. Finally, the SID presentation will include
data on the efficacy of CD101 as a potential treatment for
dermatophytosis and onychomycosis, fungal infections of the skin
and nails.
Details of the Cidara ECCMID and SID 2017 presentations are as
follows:
ECCMID 2017 Presentations
Oral Presentation:
Title: In-vitro characterization of
antibacterial activity, cidality and spontaneous resistance
potential of CD201,a novel lipopolysaccharide-binding antibacterial
immunotherapy; J. Locke, et. al. (Abstract 6210)
Date and time: Monday, April 24
from 10:24 a.m. – 10:34 a.m. Central European Daylight Time
(CEDT)
Location: Reed Messe Wien, Hall
K
Presentation number: OS0566
Session: New drugs against
Gram-negatives: from discovery to late-stage development
Poster Presentations:
Title: Susceptibility of recent
Candida auris isolates to the novel echinocandin CD101 and
comparatorantifungal agents; M.A. Ghannoum, et. al. (Abstract
9037)
Date and Time: Saturday, April 22
from 8:45 a.m. – 3:30 p.m. CEDT
Location: Reed Messe Wien, ePoster
Viewing Area
Presentation number: EV0128
Session: Fungal infection &
disease
Title: Antibacterial activity of
CD201, a novel lipopolysaccharide-binding antibacterial
immunotherapy,against recent Gram-negative clinical isolates,
including colistin-resistant strains; J. Locke, et. al. (Abstract
7345)
Date and time: Saturday, April 22
from 3:30 p.m. – 4:30 p.m. CEDT
Location: Reed Messe Wien, Paper
Poster Area
Presentation number: P0475
Session: New antibody and
immunomodulatory approaches
Title: Prophylactic, single-dose,
subcutaneous (SC) administration of CD101 shows robust efficacyin
neutropenic mouse models of candidiasis and aspergillosis; V. Ong,
et. al. (Abstract 3008)
Date and time: Monday, April 24
from 1:30 p.m. – 2:30 p.m. with ePoster Discussion from 2:06 p.m. –
2:11 p.m. CEDT
Location: Reed Messe Wien, ePoster
Arena 5
Presentation number: EP0703
Session: Candida infections: from
changing epidemiology to changing treatment
All ECCMID abstracts are available on the conference website at
www.eccmidlive.org.
SID 2017 Poster Presentation
Title: Efficacy of CD101, a novel
echinocandin, in the treatment of dermatophytosisusing a guinea pig
(GP) model; C.L. Hager, et. al.
Date and time: Friday, April 28
from 12:00 p.m. – 1:00 p.m. Pacific Daylight Time
Location: Oregon Convention Center,
Exhibit Hall A Foyer
Abstract number: 689
Session: Selected ePoster
Discussion II – Pharmacology and drug development
Copies of these presentations and posters will be available on
the Cidara website following the meetings:
http://www.Cidara.com/
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
CD101 IV, through Phase 2 and developing CD201, its bispecific
antibiotic immunotherapy, for the treatment of multi-drug resistant
Gram-negative bacterial infections. CD101 IV has enhanced potency
and is the only once-weekly therapy intended for the treatment and
prevention of life-threatening invasive fungal infections. CD201 is
the first drug candidate selected from Cidara’s novel Cloudbreak™
platform, the first immunotherapy discovery platform designed
specifically to create compounds that direct a patient’s immune
cells to attack and eliminate bacterial, fungal or viral pathogens.
Cidara recently received a grant for up to $6.9 million from CARB-X
(Combating Antibiotic Resistant Bacteria Accelerator) to advance
the development of CD201. Cidara is headquartered in San Diego,
California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effectiveness, safety, and other attributes of CD101 and CD201
and other potential product candidates, including the potential for
these compounds to successfully treat fungal or bacterial
infections, including those caused by resistant pathogens, and
potentially transform the way infectious diseases are treated, and
the potential for the Cloudbreak platform to result in future drug
candidates. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success and timing of
Cidara’s preclinical studies and clinical trials; regulatory
developments in the United States and foreign countries; changes in
Cidara’s plans to develop and commercialize its product candidates;
Cidara’s ability to obtain additional financing; Cidara’s ability
to obtain and maintain intellectual property protection for its
product candidates; and the loss of key scientific or management
personnel. These and other risks and uncertainties are described
more fully in Cidara’s Form 10-K most recently filed with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Cidara undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170417005290/en/
Cidara TherapeuticsINVESTORSWestwicke Partners, LLCRobert
H. Uhl, 858-356-5932Managing
Directorrobert.uhl@westwicke.comorMEDIASam Brown Inc.Christy
Curran, 615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
